nzschooltech

Introduction On Health Care Renewal, we frequently discuss deceptive marketing schemes designed to sell tests and treatments whose benefits for patients do not clearly outweigh their harms, and sometimes which are useless or dangerous.  In fact, we have to be selective about discussing such cases, because they are all too common.  Therefore, we tend to focus on cases involving the biggest

The Hahnemann Tragedy: Not All That Anechoic, But How Relevant Anyway? There are so many health policy narratives right now entering new phases: CMS's head slamming the very idea of a public option; prescription drug costs; the opiate crisis now including both the Sacklers and J&D--all repeatedly subjects of this blog. So my dander's up over all these things more than something maybe unique to

In 2017, we noted that President Trump had appointed a member of his Council of Economic Advisers who previously was a master corporate stealth health policy advocate.  Now he is getting a promotion. Prof Tomas Philipson to be Named to Chair of the President's Council of Economic Advisers On June 29, the Washington Post reported, President Trump plans to name economist Tomas Philipson as the

Those who cannot remember the past are condemned to repeat it. [George Santayana] The impending closure of a big teaching hospital in Philadelphia did not get much national attention, but should have. The Closing of Hahnemann University Hospital On June 26, 2019, the Philadelphia Inquirer reported: Hahnemann University Hospital will close in early September, with the wind-down of

It has been less than six weeks since our last post on the revolving door.  That post emphasized cases of the outgoing revolving door, that is, of people leaving leadership positions in governmental bodies which regulate health care or make health care policy, then soon obtaining jobs in the health care industry, particularly organizations which they previously regulated or were

It used to be all about the money. We had previously noted deceptive public relations practices, including orchestrated stealth health policy advocacy campaigns, to sell health policies favoring big health care corporations.  Third party strategies used patient advocacy organizations and medical societies that had institutional conflicts of interest due to their funding from companies selling

It used to be so simple.  Yes, we had to cope with deception in marketing.  Commercial sponsors of clinical research were known to manipulate the research, and even suppress research with results unfavorable to them.  Key opinion leaders spun medical education and the media.  But it was all releatively straightforward in some senses.  It was all at least mostly based on medical knowledge and